RE: Attractive business model13 Jan 2025 09:40
"We remain focused on meeting our stated goal of achieving cash flow breakeven without needing to raise additional funds."
This was from the Half-year Report issued on the 19th November 2024. This was BEFORE they received their grant funding approval. Reading between the lines, one more contract and they will have probably achieved this goal and possibly move into profitability, which is a complete game changer for pretty much anything on AIM.
Happy for this share price to drop all day long as it provides a fantastic buying opportunity for those bothered to read a few lines of their regulatory news.
Commenting on the interim results, Adrian Kinkaid, CEO of Fusion Antibodies plc, said: "These interim figures bear witness to the significant improvements to the business and the more favourable market conditions we have deservedly enjoyed in the period. The Company is now well positioned, generating the financial evidence of a significant recovery and promising growth in the Company's prospects. Of particular note is the increase in margins complementing the more than doubling of revenues, which is testament to the Board's and the team's determination to move toward profitability. We remain focused on meeting our stated goal of achieving cash flow breakeven without needing to raise additional funds."